Immunoexpression of bone morphogenetic protein-2 (BMP-2), BMP receptor type IA, and BMP receptor type II in metastatic and non-metastatic lower lip squamous cell carcinoma

Journal of Oral Pathology and Medicine

Volumn 40, Issue 2, 2011, Pages 181-186

  De Carvalho, Cyntia H P ^a   Nonaka, Cassiano F W ^a   De Araújo, Cristina R F ^b   De Souza, Lélia B ^a   Pinto, Leão P ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^b FEDERAL UNIVERSITY OF CAMPINA GRANDE   (Brazil)

Author keywords

Bone morphogenetic protein; Bone morphogenetic protein receptor; Lower lip; Squamous cell carcinoma

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; BONE MORPHOGENETIC PROTEIN RECEPTOR 2;

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIP CARCINOMA; LOWER LIP; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGIONAL METASTASIS; SQUAMOUS CELL CARCINOMA;

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOENZYME TECHNIQUES; LIP NEOPLASMS; LYMPHATIC METASTASIS; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC;

EID: 79251568304     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2010.00974.x     Document Type: Article

References (37)

1. Morselli P, Masciotra L, Pinto V, Zollino I, Brunelli G, Carinci F. Clinical parameters in T1N0M0 lower lip squamous cell carcinoma. J Craniofac Surg 2007; 18: 1079-82.
2. Moore S, Johnson N, Pierce A, Wilson D. The epidemiology of lip cancer: a review of global incidence and aetiology. Oral Dis 1999; 5: 185-95.
3. Luna-Ortiz K, Güemes-Meza A, Villavicencio-Valencia V, Mosqueda-Taylor A. Lip cancer experience in Mexico. An 11-year retrospective study. Oral Oncol 2004; 40: 992-9.
4. Abreu MAMM, Pimentel DRN, Silva OMP, et al. Squamous cell carcinoma of the lip: assessment of prognostic factors. Rev Bras Otorrinolaringol 2004; 70: 765-70.
5. Hardisson D. Molecular pathogenesis of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2003; 260: 502-8.
6. Hasson O. Squamous cell carcinoma of the lower lip. J Oral Maxillofac Surg 2008; 66: 1259-62.
7. Gazzerro E, Canalis E. Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 2006; 7: 51-65.
8. Blanco Calvo M, Bolós Fernández V, Medina Villaamil V, Aparicio Gallego G, Díaz Prado S, Grande Pulido E. Biology of BMP signalling and cancer. Clin Transl Oncol 2009; 11: 126-37.
9. von Bubnoff A, Cho KW. Intracellular BMP signaling regulation in vertebrates: pathway or network? Dev Biol 2001; 239: 1-14.
10. Hardwick JC, Van Den Brink GR, Bleuming SA, et al. Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology 2004; 126: 111-21.
11. Nohe A, Keating E, Knaus P, Petersen NO. Signal transduction of bone morphogenetic protein receptors. Cell Signal 2004; 16: 291-9.
12. Soares AF, Xavier RL, da Costa Miguel MC, de Souza LB, Pinto LP. Bone morphogenetic protein-2/4 and bone morphogenetic protein receptor type IA expression in metastatic and nonmetastatic oral squamous cell carcinoma. Am J Otolaryngol 2010; 31: 266-71.
13. Hsu MY, Rovinsky S, Penmatcha S, Herlyn M, Muirhead D. Bone morphogenetic proteins in melanoma: angel or devil? Cancer Metastasis Rev 2005; 24: 251-63.
14. Bryne M. Is the invasive front of an oral carcinoma the most important area for prognostication? Oral Dis 1998; 4: 70-7.
15. Da Silveira EJ, Miguel MC, Lima KC, Freitas Rde A, de Morais Mde L, Queiroz LM. Analysis of local immunity in squamous cell carcinoma of the tongue and lower lip. Exp Mol Pathol 2010; 88: 171-5.
16. Raida M, Sarbia M, Clement JH, Adam S, Gabbert HE, Höffken K. Expression, regulation and clinical significance of bone morphogenetic protein 6 in esophageal squamous-cell carcinoma. Int J Cancer 1999; 83: 38-44.
17. Fernández-Angel I, Rodríguez-Archilla A, Aneiros Cachaza J, Muñoz Medina M, Serrano Ortega S. Markers of metastasis in lip cancer. Eur J Dermatol 2003; 13: 276-9.
18. Horta MC, de Assis LA, de Souza AF, de Araújo VC, Gomez RS, Aguiar MC. p53 and p21WAF1/CIP1 overexpression at the invasive front of lower lip squamous cell carcinoma. J Oral Pathol Med 2007; 36: 88-92.
19. Arnold SF, Tims E, Mcgrath BE. Identification of bone morphogenetic proteins and their receptors in human breast cancer cell lines: importance of BMP2. Cytokine 1999; 11: 1031-7.
20. Jin Y, Tipoe GL, Liong EC, Lau TY, Fung PC, Leung KM. Overexpression of BMP-2/4, -5 and BMPR-IA associated with malignancy of oral epithelium. Oral Oncol 2001; 37: 225-33.
21. Thawani JP, Wang AC, Than KD, Lin CY, La Marca F, Park P. Bone morphogenetic proteins and cancer: review of the literature. Neurosurgery 2010; 66: 233-46.
22. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 2006; 25: 435-57.
23. Rothhammer T, Braig S, Bosserhoff AK. Bone morphogenetic proteins induce expression of metalloproteinases in melanoma cells and fibroblasts. Eur J Cancer 2008; 44: 2526-34.
24. Kang MH, Kim JS, Seo JE, Oh SC, Yoo YA. BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Exp Cell Res 2010; 316: 24-37.
25. Hou CH, Hsiao YC, Fong YC, Tang CH. Bone morphogenetic protein-2 enhances the motility of chondrosarcoma cells via activation of matrix metalloproteinase-13. Bone 2009; 44: 233-42.
26. Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic protein receptors and signal transduction. J Biochem 2010; 147: 35-51.
27. Nohe A, Hassel S, Ehrlich M, et al. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 2002; 277: 5330-8.
28. Dolado I, Nebreda AR. Regulation of tumorigenesis by p38αMAP kinase. In: Posas F, Nebreda AR, eds. Topics in Current Genetics: Stress-Activated Protein Kinases. Heidelberg: Springer, 2008; 99-128.
29. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9: 537-49.
30. Junttila MR, Ala-Aho R, Jokilehto T, et al. p38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene 2007; 26: 5267-79.
31. Scully C, Bagan JV. Oral squamous cell carcinoma: overview of current understanding of aetiopathogenesis and clinical implications. Oral Dis 2009; 15: 388-99.
32. Bagan JV, Scully C. Recent advances in Oral Oncology 2008; squamous cell carcinoma aetiopathogenesis and experimental studies. Oral Oncol 2009; 45: e45-8.
33. Davies SR, Watkins G, Douglas-Jones A, Mansel RE, Jiang WG. Bone morphogenetic proteins 1 to 7 in human breast cancer, expression pattern and clinical/prognostic relevance. J Exp Ther Oncol 2008; 7: 327-38.
34. Bieniasz M, Oszajca K, Eusebio M, Kordiak J, Bartkowiak J, Szemraj J. The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients. Lung Cancer 2009; 66: 319-26.
35. Kim IY, Lee DH, Lee DK, et al. Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1. Cancer Res 2004; 64: 7355-60.
36. Chen D, Ji X, Harris MA, et al. Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages. J Cell Biol 1998; 142: 295-305.
37. Panchision DM, Pickel JM, Studer L, et al. Sequential actions of BMP receptors control neural precursor cell production and fate. Genes Dev 2001; 15: 2094-110.